Self-Study Resources-Updates in Pleural Disease for 2023

Video Transcription

Video Summary

The update on pleural disease session at the conference discussed various aspects of pleural disease, including pleural physiology, perinominumonic infection, and malignant pleural fusion. The landscape of pleural disease has expanded over the years, with an increase in literature and guidelines to guide evidence-based care. The estimated cost of pleural disease to the US healthcare system in 2016 was over $10 billion, with non-malignant pleural disease contributing the most to the cost. However, malignant pleural fusion was found to be the most common type of pleural disease, with 65% of patients admitted or presenting to the ER having non-malignant pleural fusion. There were discussions on the management of pleural infections, with recommendations on antibiotic therapy and the use of intrapleural enzyme therapy. The importance of treating the underlying organ dysfunction in non-malignant pleural fusion was highlighted, but a recent study showed that indwelling pleural catheter versus repeat therapeutic thoracentesis had no significant difference in outcomes. The sessions also discussed the increasing incidence of pleural effusions, particularly in lung and breast cancer patients, and the need for early intervention and surgical referral for best outcomes. Overall, the sessions provided updates on the diagnosis and management of pleural disease and highlighted the importance of tailoring treatment to the individual patient.

Meta Tag

Category Disorders of the Pleura

Session ID 1060

Speaker George Cheng

Speaker Labib Debiane

Speaker Saadia Faiz

Speaker Yun Chor, Gary Lee

Track Disorders of the Pleura

Keywords

pleural disease

pleural physiology

perinominumonic infection

malignant pleural fusion

literature

guidelines

evidence-based care

US healthcare system

cost